IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33801-z.html
   My bibliography  Save this article

Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19

Author

Listed:
  • Nicolas Prost

    (Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris (AP-HP)
    Université Paris-Est-Créteil (UPEC)
    Université Paris-Est-Créteil (UPEC))

  • Etienne Audureau

    (Université Paris-Est-Créteil (UPEC)
    Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris (AP-HP)
    IMRB INSERM U955, Team CEpiA)

  • Nicholas Heming

    (Hôpital Raymond Poincaré, Assistance Publique—Hôpitaux de Paris (AP-HP))

  • Elyanne Gault

    (Hôpital Ambroise Paré, Assistance Publique—Hôpitaux de Paris (AP-HP))

  • Tài Pham

    (Université Paris-Est-Créteil (UPEC)
    Assistance Publique—Hôpitaux de Paris, Hôpital de Bicêtre, DMU 4 CORREVE Maladies du Cœur et des Vaisseaux, FHU Sepsis
    Inserm U1018, Equipe d’Epidémiologie respiratoire intégrative, CESP)

  • Amal Chaghouri

    (Assistance Publique—Hôpitaux de Paris)

  • Nina Montmollin

    (Médecine Intensive Réanimation, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris)

  • Guillaume Voiriot

    (Médecine Intensive Réanimation, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris)

  • Laurence Morand-Joubert

    (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
    Laboratoire de virologie, Hôpital Saint-Antoine, Assistance Publique—Hôpitaux de Paris)

  • Adrien Joseph

    (Médecine Intensive Réanimation, Hôpital Saint-Louis, Assistance Publique—Hôpitaux de Paris)

  • Marie-Laure Chaix

    (Université de Paris, Inserm HIPI
    Laboratoire de Virologie, Hôpital Saint-Louis, Assistance Publique—Hôpitaux de Paris)

  • Sébastien Préau

    (U1167—RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, University Lille, Inserm, CHU Lille, Institut Pasteur de Lille)

  • Raphaël Favory

    (U1167—RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, University Lille, Inserm, CHU Lille, Institut Pasteur de Lille)

  • Aurélie Guigon

    (Service de virologie, CHU de Lille)

  • Charles-Edouard Luyt

    (Sorbonne Université, Assistance Publique—Hôpitaux de Paris, Hôpital Pitié–Salpêtrière, Médecine Intensive Réanimation
    INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition)

  • Sonia Burrel

    (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
    Département de Virologie, Hôpital Pitié–Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP))

  • Julien Mayaux

    (Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Hôpital Pitié–Salpêtrière, Médecine Intensive Réanimation)

  • Stéphane Marot

    (Département de Virologie, Hôpital Pitié–Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP))

  • Damien Roux

    (Université de Paris, APHP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation
    INSERM U1151, CNRS UMR 8253, Institut Necker-Enfants Malades (INEM), Department of Immunology, Infectiology and Hematology)

  • Diane Descamps

    (Université de Paris, IAME INSERM UMR 1137, Service de Virologie, Hôpital Bichat-Claude Bernard, Assistance Publique—Hôpitaux de Paris)

  • Sylvie Meireles

    (Service de Réanimation médico-chirurgicale, Assistance Publique–Hôpitaux de Paris, Hôpital Ambroise Paré)

  • Frédéric Pène

    (Médecine Intensive Réanimation, Hôpital Cochin, Assistance Publique—Hôpitaux de Paris)

  • Flore Rozenberg

    (Laboratoire de Virologie, Hôpital Cochin, Assistance Publique—Hôpitaux de Paris)

  • Damien Contou

    (Service de Réanimation, Hôpital Victor Dupouy)

  • Amandine Henry

    (Service de Virologie, Hôpital Victor Dupouy)

  • Stéphane Gaudry

    (Service de Réanimation, Hôpital Avicenne, Assistance Publique—Hôpitaux de Paris)

  • Ségolène Brichler

    (Laboratoire de Virologie, Hôpital Avicenne, Assistance Publique—Hôpitaux de Paris)

  • Jean-François Timsit

    (Service de Médecine Intensive Réanimation, Hôpital Bichat, Assistance Publique—Hôpitaux de Paris)

  • Antoine Kimmoun

    (Université de Lorraine, CHRU de Nancy, Médecine Intensive et Réanimation Brabois
    INSERM U942 and U1116, F-CRIN-INIC RCT)

  • Cédric Hartard

    (Service de Virologie, CHRU de Nancy)

  • Louise-Marie Jandeaux

    (INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), CRBS (Centre de Recherche en Biomédecine de Strasbourg), FMTS (Fédération de Médecine Translationnelle de Strasbourg), University of Strasbourg
    Nouvel Hôpital Civil, Hôpital Universitaire de Strasbourg)

  • Samira Fafi-Kremer

    (Nouvel Hôpital Civil, Hôpital Universitaire de Strasbourg)

  • Paul Gabarre

    (Sorbonne Université, Assistance Publique—Hôpitaux de Paris, Hôpital Saint-Antoine, Médecine Intensive Réanimation)

  • Malo Emery

    (Service de Réanimation, Hôpital Saint-Camille)

  • Claudio Garcia-Sanchez

    (Laboratoire de Biologie, Hôpital Saint-Camille)

  • Sébastien Jochmans

    (Service de Réanimation Polyvalente, Hôpital Marc Jacquet)

  • Aurélia Pitsch

    (Laboratoire de Microbiologie, Hôpital Marc Jacquet)

  • Djillali Annane

    (Hôpital Raymond Poincaré, Assistance Publique—Hôpitaux de Paris (AP-HP))

  • Elie Azoulay

    (Médecine Intensive Réanimation, Hôpital Saint-Louis, Assistance Publique—Hôpitaux de Paris)

  • Armand Mekontso Dessap

    (Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris (AP-HP)
    Université Paris-Est-Créteil (UPEC)
    Université Paris-Est-Créteil (UPEC))

  • Christophe Rodriguez

    (Université Paris-Est-Créteil (UPEC)
    Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris
    INSERM U955, Team « Viruses, Hepatology, Cancer »)

  • Jean-Michel Pawlotsky

    (Université Paris-Est-Créteil (UPEC)
    Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris
    INSERM U955, Team « Viruses, Hepatology, Cancer »)

  • Slim Fourati

    (Université Paris-Est-Créteil (UPEC)
    Hôpitaux Universitaires Henri Mondor, Assistance Publique—Hôpitaux de Paris
    INSERM U955, Team « Viruses, Hepatology, Cancer »)

Abstract

Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection with variant Delta, with rarer occurrence of severe disease requiring intensive care. Little information is available on comorbid factors, clinical conditions and specific viral mutational patterns associated with the severity of variant Omicron infection. In this multicenter prospective cohort study, patients consecutively admitted for severe COVID-19 in 20 intensive care units in France between December 7th 2021 and May 1st 2022 were included. Among 259 patients, we show that the clinical phenotype of patients infected with variant Omicron (n = 148) is different from that in those infected with variant Delta (n = 111). We observe no significant relationship between Delta and Omicron variant lineages/sublineages and 28-day mortality (adjusted odds ratio [95% confidence interval] = 0.68 [0.35–1.32]; p = 0.253). Among Omicron-infected patients, 43.2% are immunocompromised, most of whom have received two doses of vaccine or more (85.9%) but display a poor humoral response to vaccination. The mortality rate of immunocompromised patients infected with variant Omicron is significantly higher than that of non-immunocompromised patients (46.9% vs 26.2%; p = 0.009). In patients infected with variant Omicron, there is no association between specific sublineages (BA.1/BA.1.1 (n = 109) and BA.2 (n = 21)) or any viral genome polymorphisms/mutational profile and 28-day mortality.

Suggested Citation

  • Nicolas Prost & Etienne Audureau & Nicholas Heming & Elyanne Gault & Tài Pham & Amal Chaghouri & Nina Montmollin & Guillaume Voiriot & Laurence Morand-Joubert & Adrien Joseph & Marie-Laure Chaix & Séb, 2022. "Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33801-z
    DOI: 10.1038/s41467-022-33801-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33801-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-33801-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Raquel Viana & Sikhulile Moyo & Daniel G. Amoako & Houriiyah Tegally & Cathrine Scheepers & Christian L. Althaus & Ugochukwu J. Anyaneji & Phillip A. Bester & Maciej F. Boni & Mohammed Chand & Wonderf, 2022. "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa," Nature, Nature, vol. 603(7902), pages 679-686, March.
    2. Akatsuki Saito & Takashi Irie & Rigel Suzuki & Tadashi Maemura & Hesham Nasser & Keiya Uriu & Yusuke Kosugi & Kotaro Shirakawa & Kenji Sadamasu & Izumi Kimura & Jumpei Ito & Jiaqi Wu & Kiyoko Iwatsuki, 2022. "Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation," Nature, Nature, vol. 602(7896), pages 300-306, February.
    3. Heidi Ledford, 2021. "How severe are Omicron infections?," Nature, Nature, vol. 600(7890), pages 577-578, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Fanglei Zuo & Hassan Abolhassani & Likun Du & Antonio Piralla & Federico Bertoglio & Leire Campos-Mata & Hui Wan & Maren Schubert & Irene Cassaniti & Yating Wang & Josè Camilla Sammartino & Rui Sun & , 2022. "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    2. Alvin X. Han & Emma Hannay & Sergio Carmona & Bill Rodriguez & Brooke E. Nichols & Colin A. Russell, 2023. "Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    3. Joseph A. Lewnard & Vennis Hong & Jeniffer S. Kim & Sally F. Shaw & Bruno Lewin & Harpreet Takhar & Sara Y. Tartof, 2023. "Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    4. X. Tong & R. P. McNamara & M. J. Avendaño & E. F. Serrano & T. García-Salum & C. Pardo-Roa & H. L. Bertera & T. M. Chicz & J. Levican & E. Poblete & E. Salinas & A. Muñoz & A. Riquelme & G. Alter & R., 2023. "Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    5. Dapeng Li & David R. Martinez & Alexandra Schäfer & Haiyan Chen & Maggie Barr & Laura L. Sutherland & Esther Lee & Robert Parks & Dieter Mielke & Whitney Edwards & Amanda Newman & Kevin W. Bock & Mahn, 2022. "Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    6. Meriem Bekliz & Kenneth Adea & Pauline Vetter & Christiane S. Eberhardt & Krisztina Hosszu-Fellous & Diem-Lan Vu & Olha Puhach & Manel Essaidi-Laziosi & Sophie Waldvogel-Abramowski & Caroline Stephan , 2022. "Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    7. Sapna Sharma & Thomas Vercruysse & Lorena Sanchez-Felipe & Winnie Kerstens & Madina Rasulova & Lindsey Bervoets & Carolien Keyzer & Rana Abdelnabi & Caroline S. Foo & Viktor Lemmens & Dominique Loover, 2022. "Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    8. Emanuele Andreano & Ida Paciello & Silvia Marchese & Lorena Donnici & Giulio Pierleoni & Giulia Piccini & Noemi Manganaro & Elisa Pantano & Valentina Abbiento & Piero Pileri & Linda Benincasa & Ginevr, 2022. "Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    9. Zhennan Zhao & Yufeng Xie & Bin Bai & Chunliang Luo & Jingya Zhou & Weiwei Li & Yumin Meng & Linjie Li & Dedong Li & Xiaomei Li & Xiaoxiong Li & Xiaoyun Wang & Junqing Sun & Zepeng Xu & Yeping Sun & W, 2023. "Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    10. Kaiyuan Sun & Stefano Tempia & Jackie Kleynhans & Anne Gottberg & Meredith L. McMorrow & Nicole Wolter & Jinal N. Bhiman & Jocelyn Moyes & Maimuna Carrim & Neil A. Martinson & Kathleen Kahn & Limakats, 2023. "Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    11. Rajeshwer S. Sankhala & Kerri G. Lal & Jaime L. Jensen & Vincent Dussupt & Letzibeth Mendez-Rivera & Hongjun Bai & Lindsay Wieczorek & Sandra V. Mayer & Michelle Zemil & Danielle A. Wagner & Samantha , 2024. "Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    12. Tomokazu Tamura & Jumpei Ito & Keiya Uriu & Jiri Zahradnik & Izumi Kida & Yuki Anraku & Hesham Nasser & Maya Shofa & Yoshitaka Oda & Spyros Lytras & Naganori Nao & Yukari Itakura & Sayaka Deguchi & Ri, 2023. "Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    13. Cassia Wagner & Kathryn E. Kistler & Garrett A. Perchetti & Noah Baker & Lauren A. Frisbie & Laura Marcela Torres & Frank Aragona & Cory Yun & Marlin Figgins & Alexander L. Greninger & Alex Cox & Hann, 2024. "Positive selection underlies repeated knockout of ORF8 in SARS-CoV-2 evolution," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    14. Alief Moulana & Thomas Dupic & Angela M. Phillips & Jeffrey Chang & Serafina Nieves & Anne A. Roffler & Allison J. Greaney & Tyler N. Starr & Jesse D. Bloom & Michael M. Desai, 2022. "Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    15. Delphine Planas & Isabelle Staropoli & Vincent Michel & Frederic Lemoine & Flora Donati & Matthieu Prot & Francoise Porrot & Florence Guivel-Benhassine & Banujaa Jeyarajah & Angela Brisebarre & Océane, 2024. "Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    16. Duggan, Jim & Andrade, Jair & Murphy, Thomas Brendan & Gleeson, James P. & Walsh, Cathal & Nolan, Philip, 2024. "An age-cohort simulation model for generating COVID-19 scenarios: A study from Ireland's pandemic response," European Journal of Operational Research, Elsevier, vol. 313(1), pages 343-358.
    17. Lei Wang & Zhiwei Wu & Zhifang Ying & Minjie Li & Yuansheng Hu & Qun Shu & Jing Li & Huixian Wang & Hengming Zhang & Wenbin Jiao & Lin Wang & Yuliang Zhao & Qiang Gao, 2022. "Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    18. Claudia Del Vecchio & Bethan Cracknell Daniels & Giuseppina Brancaccio & Alessandra Rosalba Brazzale & Enrico Lavezzo & Constanze Ciavarella & Francesco Onelia & Elisa Franchin & Laura Manuto & Federi, 2022. "Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    19. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    20. Florian B. Mayr & Victor B. Talisa & Alexander D. Castro & Obaid S. Shaikh & Saad B. Omer & Adeel A. Butt, 2022. "COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods," Nature Communications, Nature, vol. 13(1), pages 1-6, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33801-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.